Form 4: Jazz Pharma Officer Sells Shares After RSU Vesting

Patricia Carr, SVP and Chief Accounting Officer of Jazz Pharmaceuticals, reported the acquisition of shares from RSU vesting and subsequent sales, including for tax obligations.

Summary

• Patricia Carr, SVP, Chief Accounting Officer of Jazz Pharmaceuticals plc, reported transactions involving the company's ordinary shares.
• On February 26, 2026, Carr acquired 2,223 ordinary shares at a price of $0.0, resulting from the vesting of restricted stock units.
• On the same day, February 26, 2026, Carr sold 1,253 ordinary shares at a weighted average price of $194.1119 to cover tax obligations related to the RSU vesting.
• On February 27, 2026, Carr sold an additional 1,117 ordinary shares at a price of $190.9073.
• Following these transactions, Carr's direct beneficial ownership of Jazz Pharmaceuticals plc ordinary shares stands at 9,235.
• The restricted stock units are granted under the Issuer's 2011 Equity Incentive Plan and vest in equal annual installments over four years, starting from March 5, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. Form 4 filings detailing RSU vesting and subsequent sales for tax purposes are standard executive compensation activities and typically do not signal significant operational or strategic changes for the company.

Positives

• The acquisition of 2,223 ordinary shares by Patricia Carr indicates the vesting of previously granted restricted stock units, aligning with the company's equity incentive plan.

Negatives

• Patricia Carr sold a total of 2,370 ordinary shares (1,253 shares at $194.1119 and 1,117 shares at $190.9073) over two days.
• A portion of the sales (1,253 shares) was explicitly stated to satisfy tax obligations, which is a common practice but still represents a reduction in direct ownership.

Future Outlook

The filing indicates future vesting events for Patricia Carr's restricted stock units, with the first 1/4th vesting on March 5, 2027, and subsequent annual installments over the following three years.

Industry Context

StockSavvy.ai notes that insider transactions, such as those reported in a Form 4, are routine disclosures for publicly traded companies. While these specific transactions by a Chief Accounting Officer are primarily related to compensation and tax planning, they provide transparency into executive stock ownership changes. Such filings are common across the pharmaceutical industry as executives receive equity-based compensation.

Stakeholder Impact

• Shareholders: Minimal direct impact as these are routine insider transactions related to executive compensation and tax planning, not indicative of a change in company fundamentals.
• Management: Patricia Carr's direct ownership decreased slightly after the sales, but she still holds a significant number of shares, aligning her interests with shareholders.

Next Steps

• Future vesting of Patricia Carr's restricted stock units, with 1/4th vesting on March 5, 2027, and the remainder in equal annual installments over the subsequent three years.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions related to executive compensation and tax obligations. It does not provide new information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. The sales are typical for executives receiving equity compensation, and the remaining beneficial ownership still aligns the officer's interests with shareholders. Therefore, a 'hold' recommendation is appropriate as this filing alone does not present a catalyst for significant price movement or a re-evaluation of the company's fundamentals.

Keywords

Jazz Pharmaceuticals, JAZZ, Form 4, Insider Trading, Stock Sale, RSU Vesting, Executive Compensation, Patricia Carr, Equity Incentive Plan